Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Rituximab-induced splenic rupture and cytokine release
Ranjit Nair
, Shereen Gheith
, Nicholas Lamparella
Research output
:
Contribution to journal
›
Article
›
peer-review
5
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Rituximab-induced splenic rupture and cytokine release'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Rituximab
100%
Cytokine Release
100%
Splenic Rupture
100%
Mantle Cell Lymphoma
50%
Therapeutic Monoclonal Antibody
50%
Cytokine Release Syndrome
50%
Older Women
25%
Lymphoma
25%
Malignancy
25%
Clinical Course
25%
Treatment Initiation
25%
High Morbidity
25%
Chronic Lymphocytic Leukemia
25%
Risk Assessment
25%
Treatment Complications
25%
Abdominal Pain
25%
B Symptoms
25%
Further Treatment
25%
B-cell Neoplasms
25%
Case Fatality Rate
25%
High Tumor Burden
25%
Fatal Adverse Events
25%
Post-marketing Surveillance
25%
Peripheral Blood Flow Cytometry
25%
Fatal Reaction
25%
Diagnostic Challenges
25%
Chronic Lymphocytic Lymphoma
25%
Medicine and Dentistry
Rituximab
100%
Cytokine Release
100%
Spleen Rupture
100%
Neoplasm
50%
Monoclonal Antibody
50%
Mantle Cell Lymphoma
50%
Cytokine Release Syndrome
50%
Flow Cytometry
25%
Cancer
25%
Disease Course
25%
Biological Product
25%
B-Cell Chronic Lymphocytic Leukemia
25%
B Cell
25%
Morbidity
25%
B Symptoms
25%
Abdominal Pain
25%
Lymphocytic Lymphoma
25%
Peripheral Circulation
25%
Case Fatality Rate
25%
Adverse Event
25%
Pharmacology, Toxicology and Pharmaceutical Science
Cytokine
100%
Rituximab
100%
Spleen Rupture
100%
Neoplasm
50%
Monoclonal Antibody
50%
Mantle Cell Lymphoma
50%
Cytokine Release Syndrome
50%
Disease Course
25%
Adverse Event
25%
Biological Product
25%
Flow Cytometry
25%
Chronic Lymphatic Leukemia
25%
Abdominal Pain
25%
Lymphocytic Lymphoma
25%
Morbidity
25%
Postmarketing Surveillance
25%
Case Fatality Rate
25%